Embecta Corp. (EMBC)
Nasdaq · Healthcare · Medical Instruments & Supplies
$5.88+4.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $333M
- P/E (trailing)
- 4.0
- Forward P/E
- 3.3
- Dividend yield
- 0.7%
- 52-week range
- $2.77 – $14.91
- 52-week change
- −59.00%
- EPS (trailing)
- $1.47
- Next earnings
- Nov 25, 2026
Fiscal year to Sep 2025
- Revenue
- $1.1B (−3.80%)
- Net income
- $95.4M
- Operating margin
- 22.4%
- Diluted EPS
- $1.62
- Free cash flow
- $182M
From the company’s annual report on SEC EDGAR.
About Embecta Corp.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Headquarters: Parsippany, United States · 1,850 employees · embecta.com